Exelixis, Inc.
EXEL
Positions held
Your positionsEXEL isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Exelixis operates in the biotechnology sector, focusing on innovative cancer therapies, which positions it well in a growing industry with increasing demand for targeted treatments.
- Exelixis reported a revenue increase of 3% from the prior quarter, reaching $629 million.
- The company maintains a strong gross margin of 96.7%, consistent with the previous quarter.
- Despite a strong market position, Exelixis faces competition from other biotech firms developing similar cancer therapies, which could impact future growth.
- The trailing P/E ratio stands at 18.40, indicating that the stock may be overvalued compared to industry peers.
- The company's debt-to-equity ratio is 8.999, suggesting a high level of debt relative to equity, which could pose financial risks.
Fundamentals
| Market cap | $14.62B | Enterprise value | $13.95B | Trailing P/E | 18.62 | Forward P/E | 13.92 |
| PEG | 2.56 | Price / book | 7.97 | Beta | 0.47 | Dividend yield | 0.00% |
| Revenue growth | 10.6% | Earnings growth | 26.2% | Gross margin | 96.5% | Operating margin | 39.5% |
| Profit margin | 35.3% | ROE | 44.4% | ROA | 24.0% | Debt / equity | 0.09 |
| Current ratio | 3.46 | Free cash flow | $739.72M | Analyst recommendation | buy | Mean target | $54.47 |
| 52w high | $61.14 | 52w low | $33.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $629M | $611M | $599M | $598M | $568M | — |
| Op margin | 39.5% | 41.1% | 39.4% | 42.9% | 37.6% | — |
| Net income | $212M | $210M | $245M | $194M | $185M | — |
| Gross margin | 96.7% | 96.7% | 95.6% | 96.9% | 96.6% | — |
| Gross profit | $608M | $591M | $572M | $579M | $549M | — |
| Operating income | $248M | $251M | $236M | $256M | $214M | — |
- Revenue +3% vs prior quarter ($629M vs $611M).
- Gross margin 96.7% (was 96.7% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $1.8B | $1.6B |
| Op margin | 38.5% | 31.8% | 9.3% | 12.5% |
| Net income | $783M | $521M | $208M | $182M |
| Gross margin | 96.4% | 96.5% | 96.0% | 96.4% |
| Gross profit | $2.2B | $2.1B | $1.8B | $1.6B |
| Operating income | $893M | $690M | $171M | $201M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating
2026-10-08 · Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?
2026-10-08 · Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus
2026-10-07 · Is Exelixis Stock Engineered To Make You Money?
2026-10-02 · These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.
2026-10-01 · Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
2026-09-30 · Exelixis Shares Rising on CABOMETYX Revenue
2026-09-28 · FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
2026-09-24 · Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
2026-09-22 · Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?
2026-09-21 · Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer
2026-09-17 · Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B
Price (daily)
Full chart · RSI · MACD · patterns